Report cover image

HIV Vaccines Market by Antibodies (Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment), Type (Acute Paronychia, Candidal Paronychia, Chronic Paronychia), Category - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 186 Pages
SKU # IRE18444167

Description

HIV Vaccines Market by Antibodies (Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment), Type (Acute Paronychia, Candidal Paronychia, Chronic Paronychia), Category - Global Forecast 2024-2030


The HIV Vaccines Market size was estimated at USD 677.83 million in 2023 and expected to reach USD 943.11 million in 2024, at a CAGR 39.62% to reach USD 7,011.84 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the HIV Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the HIV Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the HIV Vaccines Market, highlighting leading vendors and their innovative profiles. These include AlphaVax, Inc., Antigen Express, Inc., Argos Therapeutics, Inc., Bionor Pharmaceuticals, Celldex Therapeutics, Inc., Crucell N.V., GeneCure LLC, Genetic Immunity, Inc., GenVec, Inc., GeoVax Labs, Inc., GlaxoSmithKline plc, Immune Response BioPharma, Inc., Inovio Pharmaceuticals, Inc., Novartis AG, Oncolys Biopharma, Profectus Biosciences, Sanofi SA, and TVAX Biomedical.

Market Segmentation & Coverage



This research report categorizes the HIV Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

Antibodies
Dicloxacillin
Fusidic Acid Ointment
Gentamicin Ointment
Mupirocin Ointment
Type
Acute Paronychia
Candidal Paronychia
Chronic Paronychia
Pyogenic Paronychia
Category
Preventive Vaccines
Therapeutic Vaccines
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the HIV Vaccines Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the HIV Vaccines Market?
3. What are the technology trends and regulatory frameworks in the HIV Vaccines Market?
4. What is the market share of the leading vendors in the HIV Vaccines Market?
5. Which modes and strategic moves are suitable for entering the HIV Vaccines Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

186 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. HIV Vaccines Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising investments for HIV vaccine production
5.1.1.2. Prevalence of HIV worldwide
5.1.1.3. Increasing awareness due to HIV prevention programs
5.1.2. Restraints
5.1.2.1. Issues related to HIV drug resistance
5.1.3. Opportunities
5.1.3.1. Rising affordability of HIV medicines
5.1.3.2. Increasing R&D activities for HIV vaccines clinical trials
5.1.4. Challenges
5.1.4.1. Limitations of commercialization of HIV vaccine
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. HIV Vaccines Market, by Antibodies
6.1. Introduction
6.2. Dicloxacillin
6.3. Fusidic Acid Ointment
6.4. Gentamicin Ointment
6.5. Mupirocin Ointment
7. HIV Vaccines Market, by Type
7.1. Introduction
7.2. Acute Paronychia
7.3. Candidal Paronychia
7.4. Chronic Paronychia
7.5. Pyogenic Paronychia
8. HIV Vaccines Market, by Category
8.1. Introduction
8.2. Preventive Vaccines
8.3. Therapeutic Vaccines
9. Americas HIV Vaccines Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific HIV Vaccines Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa HIV Vaccines Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AlphaVax, Inc.
13.1.2. Antigen Express, Inc.
13.1.3. Argos Therapeutics, Inc.
13.1.4. Bionor Pharmaceuticals
13.1.5. Celldex Therapeutics, Inc.
13.1.6. Crucell N.V.
13.1.7. GeneCure LLC
13.1.8. Genetic Immunity, Inc.
13.1.9. GenVec, Inc.
13.1.10. GeoVax Labs, Inc.
13.1.11. GlaxoSmithKline plc
13.1.12. Immune Response BioPharma, Inc.
13.1.13. Inovio Pharmaceuticals, Inc.
13.1.14. Novartis AG
13.1.15. Oncolys Biopharma
13.1.16. Profectus Biosciences
13.1.17. Sanofi SA
13.1.18. TVAX Biomedical
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. HIV VACCINES MARKET RESEARCH PROCESS
FIGURE 2. HIV VACCINES MARKET SIZE, 2023 VS 2030
FIGURE 3. HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HIV VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HIV VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HIV VACCINES MARKET DYNAMICS
FIGURE 7. HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2023 VS 2030 (%)
FIGURE 8. HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HIV VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 10. HIV VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HIV VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
FIGURE 12. HIV VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us